Tags

Type your tag names separated by a space and hit enter

[Statins: what is their place in the treatment of chronic kidney insufficiency?].
Rev Med Suisse. 2009 Feb 25; 5(192):463-4, 466-8.RM

Abstract

Dyslipidemia is highly prevalent in patients with chronic kidney disease (CKD), contributing to their high cardiovascular morbidity/ mortality risk and kidney damage. The lipid profile of patients with CKD commonly shows elevation of triglycerides, accumulation of atherogenic lipoproteins and decrease of HDL cholesterol. Statins are as safe and secure in CKD patients as in the general population. Used as secondary prevention in predialysis patients they seem to reduce cardiovascular mortality, but such beneficence has not been confirmed in dialysis patients. Data are still lacking in primary prevention. Ongoing studies may help to draw more precise recommendations. Meanwhile, we suggest starting lipid lowering drugs as secondary prevention in all patients at all stages of CKD.

Authors+Show Affiliations

Ponte B
Service de néphrologie, Département de médecine interne, HUG, 1211 Genève.
Bourquin V
No affiliation info available
Stoermann-Chopard C
No affiliation info available

MeSH

DyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRenal Insufficiency, Chronic

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

19317313

Citation

Ponte, Belén, et al. "[Statins: what Is Their Place in the Treatment of Chronic Kidney Insufficiency?]." Revue Medicale Suisse, vol. 5, no. 192, 2009, pp. 463-4, 466-8.
Ponte B, Bourquin V, Stoermann-Chopard C. [Statins: what is their place in the treatment of chronic kidney insufficiency?]. Rev Med Suisse. 2009;5(192):463-4, 466-8.
Ponte, B., Bourquin, V., & Stoermann-Chopard, C. (2009). [Statins: what is their place in the treatment of chronic kidney insufficiency?]. Revue Medicale Suisse, 5(192), 463-4, 466-8.
Ponte B, Bourquin V, Stoermann-Chopard C. [Statins: what Is Their Place in the Treatment of Chronic Kidney Insufficiency?]. Rev Med Suisse. 2009 Feb 25;5(192):463-4, 466-8. PubMed PMID: 19317313.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Statins: what is their place in the treatment of chronic kidney insufficiency?]. AU - Ponte,Belén, AU - Bourquin,Vincent, AU - Stoermann-Chopard,Catherine, PY - 2009/3/26/entrez PY - 2009/3/26/pubmed PY - 2009/4/25/medline SP - 463-4, 466-8 JF - Revue medicale suisse JO - Rev Med Suisse VL - 5 IS - 192 N2 - Dyslipidemia is highly prevalent in patients with chronic kidney disease (CKD), contributing to their high cardiovascular morbidity/ mortality risk and kidney damage. The lipid profile of patients with CKD commonly shows elevation of triglycerides, accumulation of atherogenic lipoproteins and decrease of HDL cholesterol. Statins are as safe and secure in CKD patients as in the general population. Used as secondary prevention in predialysis patients they seem to reduce cardiovascular mortality, but such beneficence has not been confirmed in dialysis patients. Data are still lacking in primary prevention. Ongoing studies may help to draw more precise recommendations. Meanwhile, we suggest starting lipid lowering drugs as secondary prevention in all patients at all stages of CKD. SN - 1660-9379 UR - https://www.unboundmedicine.com/medline/citation/19317313/[Statins:_what_is_their_place_in_the_treatment_of_chronic_kidney_insufficiency]_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -